Solid Biosciences Inc. Common Stock (SLDB)
Stock · NASDAQ · Health Care
$5.55as of 10/16/2026
Price chart
Active signals
SLDB Signal Track Record
How signals performed across all stocks →What SLDB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | +1.5% | 52% | September 15, 2026 |
| Bollinger Band Breakdown | 26 | -5.3% | 38% | September 15, 2026 |
| Bollinger Band Breakout | 23 | -3.5% | 43% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +8.6% | 75% | September 24, 2026 |
| Any 20-session window (baseline) | -2.6% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SLDB
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in precl…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 121
- Website
- www.solidbio.com/
Fundamentals
- 1-day range
- $5.48$5.82
- Market cap
- $857.50M
- P/E (trailing)
- —
- P/E (forward)
- -3.23
- EPS (trailing)
- $-1.91
- Dividend yield
- —
- Beta
- 2.60
- Avg. volume
- 1.14M
How Solid Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 23, 2023 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Solid Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SLDBSolid Biosciences Inc. Common Stock$5.53▼ 3.66%Market cap $857.50MP/E —$3.79$11.45
- DBVTDBV Technologies S.A. American Depositary Shares$9.05▼ 0.66%Market cap $813.58MP/E —$1.57$4.5
- AURAAura Biosciences Inc. Common Stock$6.1▼ 3.79%Market cap $798.53MP/E —$4.73$9.54
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
- CADLCandel Therapeutics Inc. Common Stock$8.19▼ 8.08%Market cap $775.20MP/E —$4.35$14
- SANASana Biotechnology Inc. Common Stock$2.27▼ 8.28%Market cap $948.97MP/E —$2.32$6.55
- ALLOAllogene Therapeutics Inc. Common Stock$1.31▼ 2.24%Market cap $679.95MP/E —$1.04$4.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SLDB Solid Biosciences Inc. Common Stock | $857.50M | — | $5.53 | ▼ 3.66% | $3.79$11.45 |
| DBVT DBV Technologies S.A. American Depositary Shares | $813.58M | — | $9.05 | ▼ 0.66% | $1.57$4.5 |
| AURA Aura Biosciences Inc. Common Stock | $798.53M | — | $6.1 | ▼ 3.79% | $4.73$9.54 |
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
| CADL Candel Therapeutics Inc. Common Stock | $775.20M | — | $8.19 | ▼ 8.08% | $4.35$14 |
| SANA Sana Biotechnology Inc. Common Stock | $948.97M | — | $2.27 | ▼ 8.28% | $2.32$6.55 |
| ALLO Allogene Therapeutics Inc. Common Stock | $679.95M | — | $1.31 | ▼ 2.24% | $1.04$4.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20benzinga · 10/15/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 10/9/2026
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/1/2026
- Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's LimitationsSeekingAlpha · 9/25/2026
- This Brinker Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga · 9/16/2026
- RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18Benzinga · 9/16/2026
- HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price TargetBenzinga · 9/14/2026
Insider Activity
Insider Actions →- SMITH IAN F · October 2, 2026 · Option Exercise3.4K
- SMITH IAN F · July 2, 2026 · Option Exercise3.4K
- Ganot Ilan · June 10, 2026 · Grant77.5K
- Georgia Keresty · June 10, 2026 · Grant77.5K
- Kahn Clare · June 10, 2026 · Grant77.5K
- Sullivan Lynne Marie · June 10, 2026 · Grant77.5K
- Adam Leo Stone · June 10, 2026 · Grant77.5K
- Freed Martin I · June 10, 2026 · Grant77.5K
- Nagendran Sukumar · June 10, 2026 · Grant77.5K
- SMITH IAN F · June 10, 2026 · Grant77.5K
- Joseph Edelman · June 10, 2026 · Grant77.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 97.19M
- Total value held
- $697.46M
- Institutional holders
- 140
- Unknown11.91M
- Unknown9.81M
- Unknown9.34M
- Unknown7.69M
- Unknown5.00M
- Unknown4.96M
- Unknown4.01M
- Unknown3.61M
- Unknown3.57M
- Unknown3.20M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SLDB Featured in After-Market Movers List
Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.
SLDB Featured in After-Market Movers List. Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.